Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + TS-1 + tislelizumab versus radiotherapy + TS-1 in elderly locally advanced esophageal squamous cell carcinoma
ChiCTR2400086933Phase 3Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tislelizumab and tegafur in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: 2-year overall survival rate. Started Jul 2024; status: recruiting.
02
Drugs
tislelizumabtegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400086933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086933.